The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care. 

Sunil Rao, MD, discusses the heart team approach in the context of deciding what is best for the patient between bypass surgery and percutaneous coronary intervention.

Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates. 

The FDA finalized four Class I recalls related to safety concerns first reported by Abbott in November. Meanwhile, a Florida man who uses these sensors to manage his diabetes has already filed a lawsuit over the issue.

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions. 

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

Researchers believe new research findings relating to the PET technique signal its potential “to meaningfully change patient care.”